United KingdomRecent reports of two child deaths linked to gene-editing treatments in China's clinical trials have intensified scrutiny of the country's fast-track trial pathway. Investigator-initiated trials (IITs), which are quicker than standard approvals under China's National Medical Products Administration, are seen as crucial for advancing biomedicine, especially in cell and gene therapies. Between 2015 and 2023, annual IIT registrations in this field increased 11-fold to 207. However, concerns arose over lax oversight, with many trials previously conducted outside designated 'sanjia' hospitals, top-tier institutions meant to ensure quality and safety. New regulations, Order 818, now restrict IITs for new biomedical technologies to sanjia hospitals, aiming to enhance oversight and reduce risks like unauthorized treatments and medical accidents.
Bias read (Center): The article presents a balanced overview of the regulatory changes and their implications, discussing both the benefits of IITs for innovation and the risks posed by insufficient oversight. It cites multiple perspectives including researchers, legal experts, and policymakers, without overtly favorit
